Silence Therapeutics’ (SLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report published on Friday,Benzinga reports. The brokerage currently has a $75.00 price target on the stock.

Several other research firms have also commented on SLN. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a report on Thursday, November 14th. Jefferies Financial Group started coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price on the stock. Finally, Morgan Stanley reissued an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Trading Down 13.2 %

Silence Therapeutics stock opened at $11.02 on Friday. The firm has a 50-day moving average price of $17.82 and a 200-day moving average price of $19.05. The firm has a market capitalization of $329.83 million, a PE ratio of -7.02 and a beta of 1.30. Silence Therapeutics has a 12-month low of $9.22 and a 12-month high of $27.72.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently modified their holdings of the company. Lombard Odier Asset Management USA Corp raised its holdings in Silence Therapeutics by 0.7% in the second quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company’s stock valued at $45,714,000 after acquiring an additional 17,086 shares in the last quarter. Redmile Group LLC purchased a new position in Silence Therapeutics in the 1st quarter valued at $43,798,000. Janus Henderson Group PLC grew its position in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after buying an additional 268,250 shares during the last quarter. Millennium Management LLC lifted its holdings in Silence Therapeutics by 91.2% in the second quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after acquiring an additional 373,523 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in Silence Therapeutics in the third quarter valued at $11,635,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.